Roya Al-Khalili

Roya Al-Khalili

Auto-generated profile, based on publicly available information

Roya Al-Khalili

The University of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
ZSZacharie Saint-Georges
Zacharie Saint-Georges
JMJulia MacDonald
Julia MacDonald
RARoya Al-Khalili
Roya Al-Khalili
RHRami Hamati
Rami Hamati
MSMarco Solm
Marco Solm
AGAnd Synthia Guimond
And Synthia Guimond
Background/Objectives Studies have shown widespread alterations in different components of the cholinergic system in schizophrenia, but to date the evidence has not been systematically reviewed and summarized. Here, we systematically review imaging and post-mortem studies on the central cholinergic system in schizophrenia/schizoaffective disorder. Subjects/Methods Searches were performed in Embase and Medline. Study designs included cross-sectional case control studies comparing individuals with schizophrenia/schizoaffective disorder to control population. Risk of bias was assessed with the NIH/NHLBI tool for Quality Assessment of Case-Control Studies. The current study followed the PRISMA 2020 guidelines (PROSPERO: CRD42023402126). Results A total of 3259 studies were screened and 61 met eligibility criteria for the systematic review, including 8 in vivo neuroimaging and 53 post-mortem studies. About 74% of these studies described significant alterations, most often reductions in either muscarinic or nicotinic receptor levels in schizophrenia. We also conducted 3 meta-analyses showing reductions in M1/M4 muscarinic receptors in the striatum (g = −0.809, k = 3, n = 108), hippocampus (g = −0.872, k = 3, n = 84), and fronto-cingulate cortex (g = −0.438, k = 4, n = 295). Six neuroimaging studies reported associations with clinical symptom severity measures, and four investigations with cognitive dysfunction. Conclusions Our review demonstrates a widespread decrease in muscarinic and nicotinic receptor levels in schizophrenia, evident in both neuroimaging and post-mortem studies. Our meta-analyses show large to moderate effects for the reductions in M1/M4 muscarinic receptors in the striatum, hippocampus, and fronto-cingulate cortex. Limitations and future directions for the field are discussed.